202 related articles for article (PubMed ID: 15374878)
1. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression.
Brown P; Levis M; Shurtleff S; Campana D; Downing J; Small D
Blood; 2005 Jan; 105(2):812-20. PubMed ID: 15374878
[TBL] [Abstract][Full Text] [Related]
2. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy.
Taketani T; Taki T; Sugita K; Furuichi Y; Ishii E; Hanada R; Tsuchida M; Sugita K; Ida K; Hayashi Y
Blood; 2004 Feb; 103(3):1085-8. PubMed ID: 14504097
[TBL] [Abstract][Full Text] [Related]
3. Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner.
Brown P; Levis M; McIntyre E; Griesemer M; Small D
Leukemia; 2006 Aug; 20(8):1368-76. PubMed ID: 16761017
[TBL] [Abstract][Full Text] [Related]
4. Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition.
Brown P; Meshinchi S; Levis M; Alonzo TA; Gerbing R; Lange B; Arceci R; Small D
Blood; 2004 Sep; 104(6):1841-9. PubMed ID: 15166029
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification.
Armstrong SA; Kung AL; Mabon ME; Silverman LB; Stam RW; Den Boer ML; Pieters R; Kersey JH; Sallan SE; Fletcher JA; Golub TR; Griffin JD; Korsmeyer SJ
Cancer Cell; 2003 Feb; 3(2):173-83. PubMed ID: 12620411
[TBL] [Abstract][Full Text] [Related]
6. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo.
Levis M; Allebach J; Tse KF; Zheng R; Baldwin BR; Smith BD; Jones-Bolin S; Ruggeri B; Dionne C; Small D
Blood; 2002 Jun; 99(11):3885-91. PubMed ID: 12010785
[TBL] [Abstract][Full Text] [Related]
7. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.
Smith BD; Levis M; Beran M; Giles F; Kantarjian H; Berg K; Murphy KM; Dauses T; Allebach J; Small D
Blood; 2004 May; 103(10):3669-76. PubMed ID: 14726387
[TBL] [Abstract][Full Text] [Related]
8. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3.
Spiekermann K; Dirschinger RJ; Schwab R; Bagrintseva K; Faber F; Buske C; Schnittger S; Kelly LM; Gilliland DG; Hiddemann W
Blood; 2003 Feb; 101(4):1494-504. PubMed ID: 12406902
[TBL] [Abstract][Full Text] [Related]
9. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation.
Ferrando AA; Armstrong SA; Neuberg DS; Sallan SE; Silverman LB; Korsmeyer SJ; Look AT
Blood; 2003 Jul; 102(1):262-8. PubMed ID: 12637319
[TBL] [Abstract][Full Text] [Related]
10. Fms-like tyrosine kinase 3 ligand stimulation induces MLL-rearranged leukemia cells into quiescence resistant to antileukemic agents.
Furuichi Y; Goi K; Inukai T; Sato H; Nemoto A; Takahashi K; Akahane K; Hirose K; Honna H; Kuroda I; Zhang X; Kagami K; Hayashi Y; Harigaya K; Nakazawa S; Sugita K
Cancer Res; 2007 Oct; 67(20):9852-61. PubMed ID: 17942916
[TBL] [Abstract][Full Text] [Related]
11. FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress.
Libura M; Asnafi V; Tu A; Delabesse E; Tigaud I; Cymbalista F; Bennaceur-Griscelli A; Villarese P; Solbu G; Hagemeijer A; Beldjord K; Hermine O; Macintyre E
Blood; 2003 Sep; 102(6):2198-204. PubMed ID: 12791658
[TBL] [Abstract][Full Text] [Related]
12. Two distinct gene expression signatures in pediatric acute lymphoblastic leukemia with MLL rearrangements.
Tsutsumi S; Taketani T; Nishimura K; Ge X; Taki T; Sugita K; Ishii E; Hanada R; Ohki M; Aburatani H; Hayashi Y
Cancer Res; 2003 Aug; 63(16):4882-7. PubMed ID: 12941810
[TBL] [Abstract][Full Text] [Related]
13. FLT3 mutations in childhood acute lymphoblastic leukemia.
Armstrong SA; Mabon ME; Silverman LB; Li A; Gribben JG; Fox EA; Sallan SE; Korsmeyer SJ
Blood; 2004 May; 103(9):3544-6. PubMed ID: 14670924
[TBL] [Abstract][Full Text] [Related]
14. D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia.
Stam RW; den Boer ML; Schneider P; Meier M; Beverloo HB; Pieters R
Haematologica; 2007 Nov; 92(11):1565-8. PubMed ID: 18024407
[TBL] [Abstract][Full Text] [Related]
15. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
Dzama MM; Steiner M; Rausch J; Sasca D; Schönfeld J; Kunz K; Taubert MC; McGeehan GM; Chen CW; Mupo A; Hähnel P; Theobald M; Kindler T; Koche RP; Vassiliou GS; Armstrong SA; Kühn MWM
Blood; 2020 Nov; 136(21):2442-2456. PubMed ID: 32589720
[TBL] [Abstract][Full Text] [Related]
16. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
O'Farrell AM; Abrams TJ; Yuen HA; Ngai TJ; Louie SG; Yee KW; Wong LM; Hong W; Lee LB; Town A; Smolich BD; Manning WC; Murray LJ; Heinrich MC; Cherrington JM
Blood; 2003 May; 101(9):3597-605. PubMed ID: 12531805
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia.
Steudel C; Wermke M; Schaich M; Schäkel U; Illmer T; Ehninger G; Thiede C
Genes Chromosomes Cancer; 2003 Jul; 37(3):237-51. PubMed ID: 12759922
[TBL] [Abstract][Full Text] [Related]
18. MLL partial tandem duplications in acute leukemia cell lines.
Quentmeier H; Reinhardt J; Zaborski M; Drexler HG
Leukemia; 2003 May; 17(5):980-1. PubMed ID: 12750714
[No Abstract] [Full Text] [Related]
19. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase.
Yee KW; O'Farrell AM; Smolich BD; Cherrington JM; McMahon G; Wait CL; McGreevey LS; Griffith DJ; Heinrich MC
Blood; 2002 Oct; 100(8):2941-9. PubMed ID: 12351406
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges.
Sternberg DW; Licht JD
Curr Opin Hematol; 2005 Jan; 12(1):7-13. PubMed ID: 15604885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]